EMA Drug Approvals 2024 | CHMP Positive Opinion | October 2024 | iPharmaCenter

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

Roche aims PNH market with SC PiaSky, aims to target AZ's Ultomiris market | iPharmaCenter

European Union Approves Ordspono for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma | iPharmaCenter

The European Commission Grants Approval for Tepkinly for a New Indication in Treating Relapsed/Refractory Follicular Lymphoma in Adults | iPharmaCenter

Dupixent (Dupilumab) Gains EU Approval as the First Targeted Therapy for COPD

Committee for Medicinal Products for Human Use | CHMP Positive Opinion | June | Europe Drug Approvals | 2024 | iPharmaCenter

European Commission Approves Roche's Alecensa as First Targeted Adjuvant Therapy for Early-Stage ALK-Positive Lung Cancer | 2024 | iPharmaCenter

Biogen Gains European Commission Approval for QALSODY (tofersen), a Novel Therapy for a Rare Genetic Form of ALS | EMA Drug Approvals | 2024 | iPharmaCenter

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter